CellaVision AB logo

CEVI - CellaVision AB Share Price

SEK342.2 -5.8  -1.7%

Last Trade - 5:00pm

Sector
Healthcare
Size
Mid Cap
Market Cap £726.5m
Enterprise Value £730.1m
Revenue £43.6m
Position in Universe 352nd / 1775
Bullish
Bearish
Unlock CEVI Revenue
Momentum
Relative Strength (%)
1m +6.08%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
216.9 239.4 265 309.3 364.8 461.8 528.6 635.7 +16.3%
+66.2 +67.9 +13.2 +16.6 +27.2 +11.8 +4.38 +36.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, CellaVision AB revenues increased 17% to SEK252.5M. Net income applicable to common stockholders decreased 18% to SEK47.5M. Revenues reflect EMEA segment increase of 63% to SEK111.4M. Net income was offset by Administration expenses increase of 39% to SEK27.1M (expense), Sales and marketing expenses increase of 15% to SEK53.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CEVI
Graphical History

Revenue

CEVI Revenue Unlock CEVI Revenue

Net Income

CEVI Net Income Unlock CEVI Revenue

Normalised EPS

CEVI Normalised EPS Unlock CEVI Revenue

PE Ratio Range

CEVI PE Ratio Range Unlock CEVI Revenue

Dividend Yield Range

CEVI Dividend Yield Range Unlock CEVI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CEVI EPS Forecasts Unlock CEVI Revenue
Profile Summary

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since May 28, 2007
No. of Shareholders: 9,286
No. of Employees: 182
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 23,851,547
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CEVI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CEVI
Upcoming Events for CEVI
Frequently Asked Questions for CellaVision AB
What is the CellaVision AB share price?

As of 5:00pm, shares in CellaVision AB are trading at SEK342.2, giving the company a market capitalisation of £726.5m. This share price information is delayed by 15 minutes.

How has the CellaVision AB share price performed this year?

Shares in CellaVision AB are currently trading at SEK342.2 and the price has moved by -0.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CellaVision AB price has moved by 8.71% over the past year.

What are the analyst and broker recommendations for CellaVision AB?

Of the analysts with advisory recommendations for CellaVision AB, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for CellaVision AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will CellaVision AB next release its financial results?

CellaVision AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the CellaVision AB dividend yield?

CellaVision AB does not currently pay a dividend.

Does CellaVision AB pay a dividend?

CellaVision AB does not currently pay a dividend.

When does CellaVision AB next pay dividends?

CellaVision AB does not currently pay a dividend.

How do I buy CellaVision AB shares?

To buy shares in CellaVision AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CellaVision AB?

Shares in CellaVision AB are currently trading at SEK342.2, giving the company a market capitalisation of £726.5m.

Where are CellaVision AB shares listed? Where are CellaVision AB shares listed?

Here are the trading details for CellaVision AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: CEVI
What kind of share is CellaVision AB?

Based on an overall assessment of its quality, value and momentum, CellaVision AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CellaVision AB share price forecast 2020?

Shares in CellaVision AB are currently priced at SEK342.2. At that level they are trading at 5.89% premium to the analyst consensus target price of 0.00.

Analysts covering CellaVision AB currently have a consensus Earnings Per Share (EPS) forecast of 4.34 for the next financial year.

How can I tell whether the CellaVision AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CellaVision AB. Over the past six months, the relative strength of its shares against the market has been 13.71%. At the current price of SEK342.2, shares in CellaVision AB are trading at 16.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CellaVision AB PE Ratio?

The CellaVision AB PE ratio based on its reported earnings over the past 12 months is 93.18. The shares are currently trading at SEK342.2.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of CellaVision AB?

CellaVision AB's management team is headed by:

Christer Fahraeus - DRC
Peter Wilson - VPR
Adam Morell - VPR
Anna Malm Bernsten - IND
Magnus Blixt - CFO
Maria Morin - VPR
Niklas Prager - IND
Zlatko Rihter - PRE
Asa Hedin - IND
Soren Mellstig - CHM
Mattias Lundin - VPR
Magnus Johnsson - VPR
Magnus Lindeberg - VPR
Jeppe Brandstrup - VBD
Juergen Riedl - IND
Who are the major shareholders of CellaVision AB?

Here are the top five shareholders of CellaVision AB based on the size of their shareholding:

Oticon Fonden Corporation
Percentage owned: 15.7% (3.75m shares)
Grenlunden CEVI AB Corporation
Percentage owned: 10.02% (2.39m shares)
Fåhraeus (Christer) Individual Investor
Percentage owned: 9.7% (2.31m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 6.5% (1.55m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 6.5% (1.55m shares)
Similar to CEVI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.